Rydapt (midostaurin) — CareFirst (Caremark)

Initial criteria

• Rydapt is used as a single agent
• Member has received first-line therapy with a clinical trial or avapritinib

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

12 months